1. Waterhouse DM, Natale RB, and Cody RL: Paraneoplastic Cerebellar Degeneration and Breast Cancer.  Cancer 68(8): 1835-1841, 1991


  1. Waterhouse DM: Smoking in Young Men with Testicular Cancer. J Clin Oncol 10(10): 1651-1652, 1992


  1. Waterhouse DM, Calzone C, Mele C, Brenner D: Adherence to Oral Tamoxifen:  A Comparison of Patient Self-Report, Pill Counts, and Microelectronic Monitoring.  J Clin Oncol 11(6): 1189-1197, 1993


  1. Waterhouse DM, Reynolds RK, Brenner DE, Natale RB: Combined Carboplatin and Cisplatin: Limited Prospects for Dose Intensification.  Cancer 71(12): 4060-4066, 1993


  1. Waterhouse DM, Brenner D: Aspirin, NSAIDs and Risk Reduction of Colon, Rectal Cancer – The Problem is Translation.  Arch Intern Med 154:366-368, 1994


  1. Doukas D, Waterhouse DM, Gorenflo D, Seid J: Attitudes and Behavior on Physician -Assisted Death: A Study of Michigan Oncologists. J Clin Oncol 13(5): 1055-1061, 1995


  1. Waterhouse DM, Carmen W, Gridley G, Schottenfeld D, McLean S: Cancer Incidence in the Rural Community of Tecumseh, Michigan: Pattern of Increased Lymphopoeitic Neoplasms. Cancer 77(4): 763-770, 1996


  1. Miller KD, Saphner TJ, Waterhouse DM, Chen TT, Rush-Taylor A, Sparano JA, Wolff AC, Cobleigh MA, Galbraith S, Sledge GW: A randomized Phase II Feasibility Trail of BMS-275291 in Patients with Early Stage Breast Cancer. Clin Cancer Res 10(6): 1971-1975, 2004


  1. Rinehart J, Adjei AA, LoRusso PM, Waterhouse DM, Hecht JR, Natale RB, Hamid O, Varterasian M, Asbury P, Kaldjian EP, Gulyas S, Mitchell DY, Herrera R, Sebolt-Leopold JS, Meyer M: A Multicenter Phase 2 Study of the Oral MEK Inhibitor, CI-1040 in Patients with Advanced Nonsmall-Cell Lung, Breast, Colon, and Pancreatic Cancer. J Clin Oncol, 2004 Nov 15; 22(22): 4456-62.


  1. Belani CP, Lee JS, Socinski MA, Robert F, Waterhouse D, Rowland K, Ansari R, Lilenbaum R, Natale RB: Randomized phase III trial comparing cisplatin-etoposide to carboplatin-paclitaxel in advanced metastatic non-small cell lung cancer. Am Oncol. 2005 July; 16(7): 1069-75.


  1. Richards DA, Boehm KA, Waterhouse DM, Wagener DJ, Krishnamurtri SS, Rosemurgy A, Grove W, Macdonald K, Gulyas S, Clark M, Dasse KD: Gemcitabine plus CI-994 offers no advantage over gemcitabine alone in treatment of patients with advanced pancreatic cancer: results of a Phase II randomized, double-blind, placebo-controlled, multicenter study. Annals of Oncology 17: 1096-1102, 2006.
  2. Belani CP, Dakhil S, Waterhouse DM, Desch CE, Rooney DK, Clark RH, Monberg MJ, Ye Z, Obasaju CK: Randomized phase II trial of gemcitabine plus weekly versus three-weekly paclitaxel in previously untreated advanced non-small-cell lung cancer.  Annals of Oncology 18(1): 110-115, 2007


  1. Beer TM, Ryan CW, Venner PM, Petrylak DP, Chatta GS, Ruether JD, Redfern CH, Fehrenbacher L, Saleh MN, Waterhouse DM, Carducci MA, Vicario D, Dreicer R, Higano CS, Ahmann FR, Chi KN, Henner WD, Arroyo A, CLow FW, ASCENT Invertigators: Double-blinded randomized study of high- dose calcitriol plus docetaxe compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators. J Clin Oncol., 2007 Feb 20; 25(6):669-74.


  1. Hainsworth JD, Spigel DR, Sosman JA, Burris HA 3rd, Farley C, Cucullu H, Yost K, Hart LL, Sylvester L, Waterhouse DM, Grecco FA: Treatment of advanced renal cell carcinoma with the combination bevacizumab/ erlotinib/imatinib: a phase I/II trial. Clin Genitourinary Cancer. 2007 Dec; 5(7):427-32.


  1. Fidias PM, Dakhil SR, Lyss AP, Loesch DM, Waterhouse DM, Bromund JL, Chen R, Hristova-Kazmierski M, Treat J, Obasaju CK, Marciniak M, Gill J, Schiller JH: Phase II of immediate compared with delayed docetaxel after frontline therapy with gemcitabine plus carboplatin in advanced non- small- cell lung cancer. J Clin Oncol. 2009 Feb 1;27(4):591-8. Epub 2008 Dec 15.


  1. Jalal S, Waterhouse DM, Edelman MJ, Nattam S, Ansari R, Koneru K, Clark R, Richards A, Wu J, Yu M, Bottema B, White A, Hanna N: Premetrexed plus cetuximab in patients with recurrent non-small cell lung cancer (NSCLC): a phase I/II study from the Hoosier Oncology Group. J Thorac Oncol. 2009 Nov. 4(11): 1420-4.


  1. Yardley DA, Burris III HA, Marcus T, Spigel DR, Grecco FA, Mainwarning M, Waterhouse DM, Webb CD, Hainsworth JD: Phase II trial of docetaxol plus imatinib mesylate in the treatment of patients with metastatic breast cancer. Clin Breast Cancer, 2009 Nov. 9(4): 237-42.


  1. Jamaal S, Waterhouse DM, Edelman MJ, Nattam S, Ansari R, Koneru K, Clark R, Richards A, Wu J, Yu M, Bottema B, White A, Hanna N: Pemetrexed Plus Cetuximab in patients with Recurrent Non-Small Cell Lung Cancer (NSCLC): A Phase I/II Study from the Hooser Oncology Group. J Thorac Oncol. 2009 Nov. 4(11): 1420-4.


  1. Hainsworth JD, Spigel DR, Thompson DS, Murphy PB, Lane CM, Waterhouse DM, Naot Y, Grecco FA: Paclitaxel/Carboplatin plus Bevacizumab/Erlotanib in the First-Line Treatment of Patients with Carcinoma of Unknown Site. Oncologist. 2009 Dec;14(12):1189-97. Epub 2009 Dec 4.


  1. Hainsworth JD, Spigel DR, Burris HA, Waterhouse DM, Clark BL, Whorf R: A Phase II Trial of Bevacizumab and Everolimus in Patients with Advanced Renal Cell Carcinoma. J Clin Oncol. 2010 May 20(13):213-6. Epub 2010 Apr 5.


  1. Spigel DR, Grecco FA, Waterhouse D, Shipley d, Lane CM, Vazquez ER, Clark BL, Infante, JR, Bendell JC, Burris HA, Hainsworth JD: Phase II Trial of FOLFOX6, Bevacizumab, and Cetuximab in the First-Line Treatment of Metastatic Colorectal Cancer. Clinical Advances in Hematology & Oncology. 2010 Jul. 8(7): 480-485.


  1. Malik SK, Waterhouse DM, Hentschel P, Gill JF, Zhoa L, Nicol SJ: Multicenter, Randomized Phase II Trial of Bevacizumab plus Folinic Acid, Fluorouracil, Gemcitabine (FFG) versus Bevacizumab plus Folinic Acid, Fluorouracil, Oxaliplatin (FOLFOX 4) as First-Line Therapy for Patients with Advance Colorectal Cancer. Investigational New Drugs. 2010 Dec. 1


  1. Madajewicz S, Waterhouse DM, Ritch PS, Khan MQ, Higby DJ, Leichman CG, Hahn NM, Stadler WM, Zon RT, Picus J, Nattam S, Johnson CS, Perkins SM, Waddell MJ, Sweeney CJ: A Phase II Trial of Cisplatin, Gemcitabine, and Bevacizumab as First-Line Therapy for Metastatic Urothelial Carcinoma: Hoosier Oncology Group GU 04-75, J Clin Oncol. 2011 Apr 20 (12): 1525-1530.


  1. Sher H, Jia X, Jia X, Chi K, Wit R, Berry W, Albers P, Henick B, Waterhouse D, Ruether D, Rosen P, Meluch A, Nordquist L, Venner P, Heidenreich A, Chu L, Heller G: A Randomized, Open-Label Phase III Trial of Docetaxel Plus High-Dose Calcitrol versus Docetaxel Plus Prednisone for Patients with Castration Resistant Prostate Cancer (ASCENT). J Clin Oncol. 2011 May: 2185-2190.


  1. Spigel DR, Townley PM, Waterhouse DM, Fang L, Adiquzel I, Huang JE, Karlin DA, Faoro L, Scappaticci FA, Socinski MA: Randomized Phase II Study of Bevacizumab in Combination with Chemotherapy in Previously Untreated Extensive-Stage Small-Cell Lung Cancer: Results from the SALUTE Trial. J Clin Oncol. 2011 Jun 1; 29(16): 2215-2222.


  1. Spigel D, Burris H, Grecco A, Shipley D, Friedman E, Waterhouse D, Whorf R, Mitchell B, Daniel D, Zangmeister J, Bass J, Hainsworth J: Randomized Double-Blind Placebo-Controlled Phase II Trial of Sorafenib and Erotinib or Erotinib Alone in Previously Treated Advanced Non-Small-Cell Lung Cancer. J Clin Oncology.  2011 June 20: 2582-2589.


  1. Spigel DR, Hainsworth JD, Shipley DL, Ervin TJ, Kohler PC, Lubiner ET, Peyton JD, Waterhouse DM, Burris HA 3rd, Grecco FA: A Randomized Phase II Trial of Pemetrexed/Gemcitabine/Bevacizumab or Pemetrexed/Carboplatin/Bevacizumab in the First-Line Treatment of Elderly Patients with Advanced Non-Small-Cell Lung Cancer. J Thoracic Oncol.  2011 Jan; 7(1): 196-202.


  1. Baselga J, Cortes J, Kim SB, Im SA, Hegg R, Im YH, Roman L, Pedrini JL, Pirnkowowski T, Knott A, Clark E, Benyunes MC, Ross G, Swain SM: CLEOPATRA Study Group. N Engl J Med. 2012 Jan 12; 366(2):109-19. Epub 2011 Dec 7.


  1. Jackson K, Guinigundo A, Waterhouse D: Bone Marrow Aspiration and Biopsy: A Guideline for Procedural Training and Competency Assessment. J Adv Prct Oncology. 2012; 3: 260-265.


  1. Madajewicz S, Waterhouse DM, Ritch PS, Khan MQ, Higby DJ, Leichman CG, Malik SK, Hentschel P, Gill JF, Zhao L, Nichol SJ. Multicenter, Randomized Phase II Study of Bevacizumab Plus Folinic Acid, Fluoruracil, Gemcitabine (FFG) versus Bevacizumab Plus Folinic Acid, Fluoruracil, Oxaliplatin (FOLFOX4) as First-Line Therapy for Patients with Advanced Colorectal Cancer. Invest New Drugs. 2012 Apr; 30(2):772-778. Epub 2010 Dec 1.


  1. Bendell JC, Meluch A, Peyton J, Rubin M, Waterhouse D, Webb C, Burris HA 3rd, Hainsworth JD. A Phase II Trial of Preoperative Concurrent Chemotherapy/Radiation Therapy plus Bevacizumab/Erlotinib in the Treatment of Localized Esophageal Cancer. Clin Adv Hematol Oncol. 2012 Jul; 10(7):430-437.


  1. Spigel DR, Anthony Grecco F, Waterhouse DM, Shipley DL, Zubkus JD, Bury MJ, Webb CD, Hart LL, Gian VG, Infante JR, Burris HA 3rd, Hainsworth JD. Phase II Trial of Ixabepilone and Carboplatin with or without Bevacizumab in Patients with Previously Untreated Advanced Non-Small-Cell Lung Cancer. Lung Cancer. 2012 Oct; 78(1):70-75. Epub 2012 Sep 1.


  1. Yardley DA, Hart L, Bosserman L, Salleh MN, Waterhouse DM, Hagan MK, Richards P, DeSailvio ML, Mahoney JM, Nagarwala Y. Phase II Study Evaluating Lapatanib in Combination with Nab-Paclitaxel in Her2-Overexpressing Metastatic Breast Cancer Patients Who Have Received No More Than One Prior Chemotherapeutic Regimen. Breast Cancer Res Treat. 2013 Jan; 137(2):457-64. Epub 2012 Dec 8.


  1. Infante JR, Arkenau HT, Bendell JC, Rubin MS, Waterhouse D, Jones GT, Spiegel DR, Lane CM, Hainsworth JD, Burris HA 3rd.. Lenalidomide in Combination with Gemcitabine as First-Line Treatment for Patients with Metastatic Carcinoma of the Pancreas. Cancer Biol Ther. Apr; 14(4):340-6. Epub 2013 Jan 28.


  1. Hainsworth JD, Waterhouse DM, Penley WC, Shipley DL, Thompson DS, Webb CD, Anthony Grecco F. Sorafenib and Everolimus in Advanced Clear Cell Renal Carcinoma: A Phase I/II Trial of the SCRI Oncology Research Consortium. Cancer Invest. 2013 Jun; 31(5):323-9. Epub 2013 Apr 24.


  1. Hainsworth JD, Shipley DL, Reeves J Jr, Arrowsmith ER, Barnes EK, Waterhouse DM. High-Dose Bevicizumab in the Treatment of Patients with Advanced Clear Cell Renal Carcinoma: A Phase II Trial of the Sarah Cannon Oncology Research Consortium. Clin Genitourin Cancer. 2013 Sep; 11(3):283-289. Epub 2013 May 15.


  1. Spigel DR, Waterhouse DM, Lane S, Legenne P, Bhatt K. Efficacy and Safety of Oral Topotecan and Bevacizumab Combination as Second-Line Treatment for Relapsed Small-Cell Lung Cancer: An Open-Label, Multicenter, Single-Arm, Phase II Study. Clinical Lung Cancer. Clin Lung Cancer. 2013 Jul; 14(4):356-63. Epub 2013 Feb 4.


  1. Yardley D, Hart L, Waterhouse DM, Whorf R, Drosick DR, Murphy P, Badarinath S, Daniel BR, Childs BH, Burris HA 3rd. Addition of Bevacizumab to Three Docetaxel Regimens as Adjuvant Therapy for Early-Stage breast Cancer. Breast Cancer Res Treat. 2013 Jan; 137(2):457-64. Epub 2012 Dec 8.


  1. Forero-Torres A, Infante JR, Waterhouse DM, Wong L, Vickers S, Arrowsmith E, He AR, Hart L, Trent D, Wade J, Jin X, Wang Q, Austin T, Rosen M, Beckman R, von Roemeling R, Greenberg J, Saleh M. Phase 2, Multicenter, Open-Label Study of Tigatuzumab (CS-1008), a Humanized Monoclonal Antibody Targeting Death Receptor 5, in Combination with Gemcitabine in Chemotherapy-Naïve Patients with Unresectable or Metastatic Pancreatic Cancer. Cancer Medicine. 2013 Dec; 2(6): 925-32. [Epub 2013 Oct 25].


  1. Zinner, Ralph G. MD; Obasaju, Coleman K. MD, PhD; Spigel, David R. MD; Weaver, Robert W. MD; Beck, J. Thaddeus MD; Waterhouse, David M. MD, MPH; Modiano, Manuel R. MD; Hrinczenko, Borys MD, PhD; Nikolinakos, Petros G. MD; Liu, Jingyi PhD; Koustenis, Andrew G. BPharm; Winfree, Katherine B. PhD; Melemed, Symantha A. PhD; Guba, Susan C. MD; Ortuzar, Waldo I. MD; Desaiah, Durisala PhD; Treat, Joseph A. MD; Govindan, Ramaswamy MD; Ross, Helen J. MD. PRONOUNCE: Randomized, Open-Label, Phase III Study of First-Line Pemetrexed + Carboplatin Followed by Maintenance Pemetrexed Versus Paclitaxel + Carboplatin + Bevacizumab Followed by Maintenance Bevacizumab in Patients with Advance Nonsquamous Non-Small Cell Lung Cancer. J Thoracic Oncol. 2015 Jan, 10 (1); 134-142. [Epub 2014 Nov 3].


  1. Weber JS, Laura A. LA, Adamson PC, Bruinooge S, Burris IIII HA 3rd, Carducci MA, Dicker AP, Gonen M, Keefe SM, Postow MA, Schuchter LE, Thompson MA, Waterhouse DM, and Susan L. Weiner SL. American Society of Clinical Oncology Policy Statement Update: The Critical Role of Phase I Trials in Cancer Research and Treatment J Clin Oncol. 2015 Jan 20; 33(3): 278-284. [Epub 2014 Dec 15].


  1. Spigel DM, Waterhouse DM, et al. Phase III Study of Gemcitabine/Carboplatin With or Without Iniparib in Patients with Previously Untreated Stage IV Squamous Non-Small-Cell Lung Cancer (NSCLC). J Clin Oncol. 2015 Mar.


  1. Brahmer J, Reckamp KL, Baas P, Crino L, Eberhardt WE, Poddubskaya E, Antonia S, Pluzanski A, Volkes EE, Holgado E, Waterhouse D, Ready N, Gainer J, Frontera OA, Havel, L, Steins M, Garassino MC, Alerts JG, Domine M, Paz-Ares L, Reck M, Baudelet C, Harbison CT, Lestini B, Spigel DR. Nilolumab versus Docetaxel in Previously Treated Patients with Advanced Squamous Non-small Cell Lung Cancer. N Engl J Med.  2015 Jul 9; 373(2): 123-35. [Epub 2015 May 31]


  1. Yu, H, Batenchuk C, Badzio A, Boyle TA, Czpiewski P, Chan DC, Lu X, Ellison K, Kowalewski AA, Rivard CJ, Dziadziuszko R, Zhou C, Hussein M, Richards D, Wilks S, Monte M, Edenfield W, GoldschmidtJ, PageR, Ulrich B, Waterhouse DM, Jassem J, Kulig K, Hirsch FR. Association of Expression of PD-L1 with the Tumor Immune Microenvironment in Small Cell Lung Cancer.  J Thoracic Oncol. 2016 Feb.


  1. Bendell JC, Zakari A, Lang E, Waterhouse D, Flora D, Alguire K, McCleod M, Peacock N, Ruehlman P, Lane CM, Earwood C, Shih K. A Phase II Study of the Combination of Bevacizumab, Pertuzumab, and Octreotide LAR for Patients with Advanced Neuroendocrine Tumors. Cancer Invest. 2016 May 27; 34(5): 213-9.  [Epub 2016 April 29]


  1. Flinn I, Stark A, Harwin W, Waterhouse D, Papish S, Jones J, Hainsworth J, Byrd JC. A Phase II Study of Two Dose Levels of Ofatumumab Induction followed by Maintenance Therapy in Symptomatic, Previously Untreated Chronic Lymphocytic Leukemia (CLL). Am J Hematol. 2016 Jul 7. doi: 10.1002/ajh.24468. [Epub ahead of print]


  1. Lee Schwartzberg, MD, David Ettinger, MD, Mohammad Jahanzeb, MD, Gregory Otterson, MD and David Waterhouse, MD. Op-Ed: Our View on Value Frameworks in Oncology: Proposing Principles for Value Framework Development. Oncology Business Review. 2016 Oct. Vol. 11, Issue 10 [Epub ahead of print]


  1. Blumenschein G Jr, Chandler J, Garon EB, Waterhouse D, Goldman JW, Gunuganti VK, Boccia R, Spigel D, Glaspy J, Berry DA, Korytowsky B, Zhu J, Lin WH, Bennett K, Reynolds C. PS01.59: CheckMate 370: A Master Protocol of Phase 1/2 Studies of Nivolumab as Maintenance or First-Line ± Standard-of-Care Therapies in Advanced NSCLC: Topic: Medical Oncology. J Thorac Oncol. 2016 Nov;11(11S):S307. doi: 10.1016/j.jtho.2016.09.094. Epub 2016 Oct.


  1. Waterhouse D, Horn L, Reynolds C, Spigel D, Chandler J, Mekhail T, Mohamed M, Creelan B, Blankstein KB, Nikolinakos P, Mccleod MJ, Li A, Waxman IM, Aanur N, Agrawal S, Richardet E. Safety Profile of Nivolumab Administered as 30-Minute (MIN) Infusion: Analysis of Data from Checkmate 153: Track: Immunotherapy. J Thorac Oncol. 2016 Oct;11(10S): S236.


  1. George B, Kelly K, Ko A, Soliman H, Trunova N, Wainberg Z, Waterhouse D, O’Dwyer P. Phase I Study of Nivolumab + Nab-Paclitaxel in Solid Tumors: Preliminary Analysis of the Non-Small Cell Lung Cancer Cohort: Track: Advanced NSCLC. J Thorac Oncol. 2016 Oct;11(10S): S211-S212.


  1. Yu H, Batenchuk C, Badzio A, Boyle TA, Czapiewski P, Chan DC, Lu X, Gao D, Ellison K, Kowalewski AA, Rivard CJ, Dziadziuszko R, Zhou C, Hussein M, Richards D, Wilks S, Monte M, Edenfield W, Goldschmidt J, Page R, Ulrich B, Waterhouse D, Close S, Jassem J, Kulig K, Hirsch FR. PD-L1 Expression by Two Complementary Diagnostic Assays and mRNA In Situ Hybridization in Small Cell Lung Cancer. J Thorac Oncol. 2017 Jan;12(1):110-120.


  1. Weber JS, Levit LA, Adamson PC, Bruinooge SS, Burris HA 3rd, Carducci MA, Dicker AP, Gönen M, Keefe SM, Postow MA, Thompson MA, Waterhouse DM, Weiner SL, Schuchter LM. Reaffirming and Clarifying the American Society of Clinical Oncology’s Policy Statement on The Critical Role of Phase I Trials in Cancer Research and Treatment. J Clin Oncol. 2017 Jan 10;35(2):139-140. Epub 2016 Nov 28.


  1. Diamond JR, Goff B, Forster MD, Bendell JC, Britten CD, Gordon MS, Gabra H, Waterhouse DM, Poole M, Ross Camidge D, Hamilton E, Moore KM. Phase Ib study of the mitochondrial inhibitor ME-344 plus topotecan in patients with previously treated, locally advanced or metastatic small cell lung, ovarian and cervical cancers. Invest New Drugs. 2017 Mar 10. doi: 10.1007/s10637-017-0444-1. [Epub ahead of print]


  1. Spigel D, MD, Mekhail T, MD, Waterhouse D, MD, MPH, Hadley T, MD, Webb C, MD, Burris III HA, MD, Hainsworth J, MD, Greco FA, MD. First Line Carboplatin, Pemetrexed, and Panitumumab in Patients with Advanced Non-Squamous KRAS Wild Type (WT) Non-Small-Cell Lung Cancer (NSCLC). Cancer Invest. 2017 Sept. Vol. 35, Issue 8: 541-546. [Aug 1:1-6. Epub ahead of print]


  1. Ko AH, Murphy PB, Peyton JD, Shipley DL, Al‐Hazzouri A, Rodriguez FA, Womack MS 4th, Xiong HQ, Waterhouse DM, Tempero MA, Guo S, Lane CM, Earwood C, DeBusk LM, Bendell JC. A Randomized, Double‐Blinded, Phase II Trial of Gemcitabine and Nab‐Paclitaxel Plus Apatorsen or Placebo in Patients with Metastatic Pancreatic Cancer: The RAINIER Trial. Oncologist. 2017 Dec;22(12):1427-e129. doi: 10.1634/theoncologist.2017-0066. Epub 2017 Sep 21.


  1. Horn L, Spigel D, Vokes E, Steins M, Poddubskaya E, Borghaei H, Felip E, Paz-Ares L, Pluzanski A, Reckamp K, Burgio M, Kohlhaeufl M, Waterhouse D, Barlesi F, Antonia S, Arrieta O, Fayette J,  Crino L,  Rizvi  N, Reck M, Hellmann M, Geese W, Li A, Blackwood-Chirchir A, Healey D, Julie Brahmer J, Eberhardt W. Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer: 2-Year Outcomes From Two Randomized, Open-label Phase III Trials (CheckMate 017 and CheckMate 057). J Clin Oncol. 2017 Dec 10;35(35):3924-3933. doi: 10.1200/JCO.2017.74.3062. Epub 2017 Oct 12.



  1. Spigel D, Reynolds C, Waterhouse D, Garon EB, Chandler J, Babu S, Thurmes P, Spira A, Jotte R, Zhu J, Lin WH, Blumenschein G. Phase 1/2 Study of the Safety and Tolerability of Nivolumab Plus Crizotinib for the First-line Treatment of ALK Translocation-Positive Advanced Non-Small Cell Lung Cancer (CheckMate 370). J Thoracic Oncol. 2018. May;13(5):682-688. Doi: 10.1016/j.jtho.2018.02.022. Epub 2018 Mar 6


  1. Waterhouse D, Horn L, Reynolds C, Spigel D, Chandler J, Mekhail T, Mohamed M, Creelan B, Blankstein K, Nikolinakos P, Mccleod MJ, Li A, Abderrahim O, Agrawal S, Aanur N. Safety Profile of Nivolumab Administered as 30-Minute (MIN) Infusion: Analysis of Data from Checkmate 153. Cancer Chemotherapy and Pharmacology. 2018 Apr;81(4):679-686. Doi; 10.1007/s00280-018-3527-6. Epub 2018 Feb 13.


  1. Spigel D, Shipley D, Mekhail T, Zubkus D, Waterhouse D, Daniel D, Burris III HA, Greco A: Amrubicin and carboplatin with pegfilgrastim in patients with extensive stage small cell lung cancer: A Phase II trial of the Sarah Cannon Oncology Research Consortium. Lung Cancer. 2018 March; 117:38-43, doi: 10.1016/j.lungcan.2018.01.007. Epub 2018 Jan 12.


  1. Spigel D, Burris III HA, Greco F, Shih K, gian V, Lipman A, Daniel D, Waterhouse D, Finney L, Heymach J, Hainsworth J. Erlotinib Plus either Pazopanib or Placebo in Patients with Previously Treated Advanced Non-Small-Cell Lung Cancer: A Randomized Placebo-controlled Phase II Trial with Correlated Serum Proteomic Signatures. Cancer. 2018 Jun 1; 124(11):2355-2364. Doi: 10.1002/cncr.31290. Epub 2018 Apr 12.


  1. Hainsworth JD, Waterhouse DM, Shih KC, Boccia RV, Priego VM, McCleod MJ, Kudrik FJ, Mitchell RB, Burris HA 3rd, Greco FA, Spiegel DR. Phase II Trial of Preoperative Pemetrexed Plus Carboplatin in Patients with Stage IB-III Nonsquamous Non-Small Cell Lung Cancer (NSCLC). Lung Cancer. 2018 Apr; 118:6-12. Doi: 10.1016/j.lungcan.2018.01.009. Epub 2018 Jan 31.


  1. Garassino MC, Cho BC, Kim JH, Mazières J, Vansteenkiste J, Lena H, Corral Jaime J, Gray JE, Powderly J, Chouaid C, Bidoli P, Wheatley-Price P, Park K, Soo RA, Huang Y, Wadsworth C, Dennis PA, Rizvi NA; ATLANTIC Investigators. Durvalumab as Third-Line or Later Treatment for Advanced Non-Small-Cell Lung Cancer (ATLANTIC): An Open-Label, Sigle-Arm, Phase 2 Study. Lancet Oncol. 2018 Apr;19(4):521-536. doi: 10.1016/S1470-2045(18)30144-X. Epub 2018 Mar 12.


  1. Vokes E, Ready N, Felip E, Horn L, Burgio M, Antonia S,  Frontera O,  Gettinger S, Holgado E, D. Spigel D,  Waterhouse D,  Domine M,  Garassino M,  Chow L, Blumenschein Jr. G,  F. Barlesi F,  Coudert B,  Gainor J,  Arrieta O,  Brahmer J,  Butts C,  Steins M,  Geese W,  Li A,  Healey D,  Crinò L. Nivolumab Versus Docetaxel in Previously Treated Advanced NSCLC (CheckMate 017 and CheckMate 057): 3-Year Update and Outcomes in Patients With Liver Metastases. Ann Oncol. 2018 Apr 1;29(4):959-965. Doi: 10.1093/annonc/mdy041.


  1. McMullen S, Hess LM, Kim ES, Levy B, Mohamed M, Waterhouse D, Wolzniak A, Goring S, Muller K, Muehlenbein C, Aggarwal H, Zhu Y, Oton AB, Ersek JL, Winfree KB: Treatment Decisions for Advanced Non-Squamous Non-Small Cell Lung Cancer: Patient and Physician Perspectives on Maintenance Therapy. 2018 Aug 21. doi: 10.1007/s40271-018-0327-3. [Epub ahead of print]


  1. Mendenhall M, Dyehouse K, Hayes J, Manzo, Meyer-Smith T, Guinigundo A, Bourbeau B, Waterhouse D. Practice Transformation – Early Impact of OCM on Hospital Admissions. J Oncol Pract. 2018 Sep 28: JOP1800409. doi: 10.1200/JOP.18.00409. [Epub ahead of print].


  1. Paz-Ares L, Luft A, Vicente D, Tafreshi A, Gümüş M, Mazières J, Hermes B, Çay Şenler F, Csőszi T, Fülöp A, Rodríguez-Cid J, Wilson J, Sugawara S, Kato T, Lee KH, Cheng Y, Novello S, Halmos B, Li X, Lubiniecki GM, Piperdi B, Kowalski DM; KEYNOTE-407 Investigators. Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer. N Engl J Med. 2018 Nov 22;379(21):2040-2051. doi: 10.1056/NEJMoa1810865. Epub 2018 Sep 25.


  1. Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, Kurata T, Chiappori A, Lee KH, de Wit M, Cho BC, Bourhaba M, Quantin X, Tokito T, Mekhail T, Planchard D, Kim YC, Karapetis CS, Hiret S, Ostoros G, Kubota K, Gray JE, Paz-Ares L, de Castro Carpeño J, Faivre-Finn C, Reck M, Vansteenkiste J, Spigel DR, Wadsworth C, Melillo G, Taboada M, Dennis PA, Özgüroğlu M; PACIFIC Investigators. Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLCA. N Engl J Med. 2018 Dec 13;379(24):2342-2350. doi: 10.1056/NEJMoa1809697. Epub 2018 Sep 25.


  1. Van der Velden DL, Levit LA, JD, Chang GJ, Facktor MA, MD, Goodman KA, MD, MS, Jeffrey Kaufman K, MBA, MIA, Konecny GE, MD, Kwan SW, MD, Mooney M, MD, MBA, Smith G, MD, PhD, MD, Solomon S, MD, Alda Tam A, MD, Waterhouse D, MD, MPH, Voest EE, MD, PhD. When Oncologic Treatment Options Outpace the Existing Evidence: Contributing Factors and a Path Forward: A Joint Statement by the American College of Surgeons Commission on Cancer, American Society for Radiation Oncology, American Society of Clinical Oncology, Society of Interventional Radiology, and Society of Surgical Oncology. Journal of Cancer Policy. 2019 Jun.


  1. Spigel DR, McCleod M, Jotte RM, Einhorn L, Horn L, Waterhouse DM, Creelan B, Babu S, Leighl NB, Chandler JC, Felix C, Keogh G, Goss G, Daniel DB, Garon EB, Schwartzberg LS, Sen R, Korytowsky B, Li A, Aanur N, Hussein MA. Safety, Efficacy and Patient-reported Health-related Quality of Life and Symptom Burden with Nivolumab in Patients with Advanced Non-Small Cell Lung Cancer, including Patients Aged ≥70 Years or with Poor Performance Status (CheckMate 153). J Thorac Oncology. 2019 May 20. Pii: S1556-0864(19)30376-4. doi: 1016/j.tho.2019.05.010. [Epub ahead of print].


  1. Spigel DR, Waterhouse D. A Randomized, Double-Blinded, Phase II Trial of Carboplatin and Pemetrexed With or Without Apatorsen (OGX-427) in Patients with Previously Untreated Stage IV Non-Squamous-Non-Small-Cell Lung Cancer: the SPRUCE Trial. Oncologist. 2019 Dec;24(12):e1409-e1416. doi: 10.1634/theoncologist.2018-0518. Epub 2019 Aug 16.


  1. Goldman JW, Waterhouse DM, George B, O’Dwyer PJ, Bhore R, Banerjee S, Lyons L, Louis CU, Ong TJ, Kelly K. Safety and Efficacy Results of a Phase I, Open-Label Study of Concurrent and Delayed Nivolumab in Combination With nab-Paclitaxel and Carboplatin in Advanced Non-Small Cell Lung Cancer. Frontiers in Oncology. 2019 Nov 26;9:1256. Doi: 10.3389/fonc.2019.01256.


  1. Liu MC, Oxnard GR, Klein EA, Swanton CM. V. Seiden CM, on behalf of the CCGA Consortium. Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA. Ann Oncol 2020 May 1;S0923-7534(20)39312-1. doi: 10.1016/j.annonc.2020.04.013.


  1. Waterhouse D, Harvey DM, Hurley P, Levit L, Kim ES, Klepin HD, Mileham KF, Nowakowski G, Schenkel, C, Davis C, Bruinooge SS, Schilsky RL. Early Impact of COVID-19 on the Conduct of Oncology Clinical Trials and Long-term Opportunities for Transformation: Findings from an American Society of Clinical Oncology Survey. JCO Oncol Pract. 2020 Jul;16(7):417-421. doi: 10.1200/OP.20.00275. Epub 2020 May 12.


  1. Wainberg Z, Hochster H, Kim E, George B, Kaylan A, Chiorean G, Waterhouse D, Gutierrez M, Parikh A, Jain R, Carrizosa D, Soliman H, Lila T, Reiss D, Pierce D, Bhore R, Banerjee S, Lyons L, Louis C, Ong T, O’Dwyer P. Open-Label, Phase 1 Study of Nivolumab Combined With nab-Paclitaxel Plus Gemcitabine in Advanced Pancreatic Cancer. Clin Cancer Res. 2020 Jun 18;clincanres.0099.2020. doi: 10.1158/1078-0432.CCR-20-0099. Online ahead of print.


  1. Waterhouse DM, Espirito JL, Chioda MD, Baidoo B, Mardekian J, Robert N, Masters ET. ALK-inhibitor Therapy Sequencing and Outcomes in Patients with ALK-positive Non-Small Cell Lung Cancer. Drugs – Real World Outcomes. 2020 July 28; 7(4): 261-269. DOI 10.1007/s40801-020-00207-6. Online ahead of print.


  1. Waterhouse DM, Garon EB, Jason Chandler J, McCleod M, Maen Hussein M, Jotte R, Horn L, Daniel DB, Keogh G, Creelan B, Einhorn LH, Baker J, Kasbari S, Nikolinakos P, Couture F, Leighl NB, Reynolds C, Blumenschein, Jr. G, Vijay Gunuganti V, Ang Li A, Aanur N, Spigel DR. Continuous Versus 1-Year Fixed-Duration Nivolumab in Advanced Lung Cancer.  J Clin Oncol. 2020 Sep 10:JCO2000131. doi: 10.1200/JCO.20.00131. Online ahead of print. PMID: 32910710 


  1. Kurbegov D, Hurley P, Waterhouse D, Robert N, Nowakowski G, Thompson M, Bruinooge S, Schilsky RL, Byatt L, Dempsey K, Dawson C, Howfacker J, Liu J, MacDougal K, Kim E. Recommendations to Streamline and Standardize Clinical Trial Site Feasibility Assessments: An ASCO Research Statement.  JCO Oncology Practice. 2021 Jan 6. doi: 10.1200/OP.20.00821. Published online January 06, 2021.


  1. Borghaei H, Gettinger S, Vokes EE, Chow L, Burgio MA, Carpeno J, Pluzanski A, Arrieta O, Frontera OA, Chiari R, Butts C, Wójcik-Tomaszewska J, Coudert B, Garassino MC, Ready N, Felip E, García MA, Waterhouse D, Domine M, Barlesi F, Antonia S, Wohlleber M, Gerber DE, Czyzewicz G, Spigel DR, Crino L, Eberhardt WE, Li A, Marimuthu S, Brahmer J. 5-Year Outcomes From the Randomized, Phase 3 Trials CheckMate 017/057: Nivolumab vs Docetaxel in Previously Treated Non-Small Cell Lung Cancer. J Clin Oncol. 2021 Jan 15. Doi: 10.1200/JCO.20.0160.  Published online January 15, 2021


  1. Waterhouse DM, Nwokeji ED, Boyd M, Penrod JR, Espirito JL, Robert NJ, Daumont MJ. Treatment Patterns and Outcomes of Patients with Advanced Malignant Pleural Mesothelioma in a Community Practice Setting. Frontiers of Cancer. Published online ahead of print on March 26, 2021


  1. Stenehjem D, Lubinga S, Betts KA, Tang W, Jenkins M, Yuan Y, Hartman J, Rao S, Lam J, Waterhouse DM. Treatment Patterns in Patients with Metastatic Non-Small Cell Lung Cancer in the Era of Immunotherapy. Future Oncology.  2021 April 14. org/10.2217/fon-2021-0230. Published online ahead of print on April 14, 2021


  1. Waterhouse DM, Lam J, Betts KA, Yin L, Goa S, Yuan Y, Hartman J, Roa S, Lubinga S, Stenehjem D. Real-World Outcomes of Immunotherapy–Based Regimens in First-Line Advanced Non-Small Cell Lung Cancer. Lung Cancer. can.2021.04.007. Published online ahead of print on April 14, 2021


  1. Waterhouse D, Lam JD, Betts KA, Yin L, Gao S, Yuan Y, Hartman J, Rao S,2 Lubinga S, Stenehjem Real-world progression-free survival in first-line advanced non-small cell lung cancer treated with immunotherapy-based regimens. Data in Brief. 2021 Jun 6;37:107195.doi: 10.1016/j.dib.2021.107195. eCollection 2021 Aug.


  1. Waterhouse DM, Tseng W, Espirito J, Robert N. Understanding contemporary molecular biomarker testing rates and trends for metastatic NSCLC among community oncologists.  Clin Lung Cancer. 2021 May 29;S1525-7304(21)00100-5.  doi: 10.1016/j.cllc.2021.05.006. Online ahead of print


  1. Mileham K, Bruinooge S, Aggarwal C, Patrick A, Davis C, Mesenhowski DJ Spira A, Clayton E, Waterhouse D, Jazieh A, Chen R, Kaltenbaugh M, Williams J, Gralow J, Schilsky R, Garrett-Mayer E. Changes over time in COVID-19 severity and mortality in patients undergoing cancer treatment in the U.S.: Initial report from the ASCO registry. JCO Oncology Practice. 2021 October 25. 10.1200/OP.21.00394. Published online ahead of print on September 21, 2021


  1. Guo MZ, Marrone KA, Spira A, Waterhouse D, Scott SC. Targeted treatment of non-small cell lung cancer: focus on capmatinib with companion diagnostics. OncoTargets and Therapy. 2021 November 23.


  1. Waterhouse D, Iadeluca L, Sneha Sura S, Wilner K, Emir B, Krulewicz S, Espirito J, Lauren Bartolome L. Real-World Outcomes Among Crizotinib Treated Patients with ROS1-Positive Advanced Non-Small Cell Lung Cancer: A Community Oncology-Based Observational Study. Targeted Oncology. 2021 December 29.


  1. Jimenez RB, Schenkel C, Levit LA,  Hu B, Lei XJ, Harvey PR, Morrison VA, Pollastro T, Waterhouse D, Weeks C, Williams GR, Bruinooge S, Garrett-Meyer E, Peppercorn J. Oncologists’ Perspectives on Individualizing Dose Selection for Patients With Metastatic Cancer. JCO Oncology Practice. 2022 November 1. DOI: 10.1200/OP.22.00427. Published online September 20, 2022.


  1. He K, Berz D, Gadgeel SM, Iams WT, Bruno DS, Blakely, CM, Spira AI, Patel MR, Waterhouse D, Richards DA, Pham A, Jotte R, Hong DS, Garon EB, Traynor A, Olsen PD, Letvan L, Yan X, Shazer R, Leal TA. MRTX-500 Phase II Trial: Sitravatinib With Nivolumab in Patients With Non-Squamous Non-Small Cell Lung Cancer Progressing On/After Checkpoint Inhibitor Therapy or Chemotherapy. Journal of Thoracic Oncology (2023), doi:


  1. De Langen AJ, Johnson ML, Mazieres J, Dingemans AC, Mountzios G, Pless M, Wolf J, Schuler M, Lena H, Skoulidis F, Okamoto I, Kim S, Linardou H, Novello S, Van der Wekken A, Chen Y, Peters S, Felip E, Solomon B, Ramalingam S, Dooms C, Lindsay CR, Ferreira C, Blais N, Obiozor C, Wang Y, Mehta B, Varrieur T, Ngarmchamnanrith G, Stollenwerk B, Waterhouse D*, Paz-Ares*, for the CodeBreaK 200 Investigators. Sotorasib versus Docetaxel for Previously Treated Lung Cancers with KRAS G12C Mutation. Lancet. Published online February 7, 2023. DOI May


*Senior Co-Authors


  1. Waterhouse D, Ward P, Drosick DR, Davies D, Mendenhall M. Closing the Testing Gap: Standardization of Comprehensive Biomarker Testing for Metastatic NSCLC in a Large Community Oncology Practice. JCO Oncology Practice. Published online May 1, 2023. DOI


  1. Mendenhall M, Guinigundo A, Davies D, Ward P, Drosick DR, Waterhouse D. Strategic Integration of Genetic Testing and Counseling in Patients with Breast Cancer in a Large Community-Based Practice. JCO Oncology Practice. Published online June 27, 2023. DOI


  1. Waterhouse D, Yong C, Frankart A, Brannman L, Mulrooney T, Robert N, Aguilar KM, Ndukum J, Cotarla I. Treatment Patterns and Outcomes among Patients with Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC) who Received Durvalumab Consolidation Therapy in a Large Community Oncology Network. Future Oncology. Accepted for Publication June 2023.


  1. Koselke E, Hough S, Howell J, Robert N, Neubauer M, Bullock S, Walberg J, Rammage M, Butrynski J, Hakimian D, Jotte R, Meshad M, Ali K, Waterhouse D, Coleman R, Evangelist, M. Impact of an oncology clinical pharmacist intervention on clinical trial enrollment in The US Oncology Network’s MYLUNG Consortium™. Journal of the Advanced Practitioner in Oncology. Accepted for Publication June 2023.


  1. Waterhouse D, Ward P, Drosick DR, Burdette C, Davies D, Mendenhall M. Sustainable integration of FDA approved biosimilars: Pharmacy versus Physician driven change. JCO Oncology Practice. Accepted for Publication August 2023.


  1. Bilder SM, Petrilla AA, Stevinsen KL, Sultan I, Jones B, Waterhouse D, Markward NJ, Stollenwerk B. Impact of Molecular Biomarker Test Availability and Timing on mNSCLC Treatment Selection and Clinical Outcomes in US Medicare Population. The Oncologist. Submitted May 2023


  1. Harvey DR, Miller TM, Hurley PA, Thota R, Black LJ, Bruinooge SS, Boehmer LM, Fleury ME, Kamboj J, Rizvi MA, Symington, BE, Tap WD, Waterhouse D, Levit, LA, Merrill, JK, Prindiville SA, Pollastro T, Brewer, JR, Byatt LP, Hamroun L, Kim ES, Holland N, Nowakowski GS. A call to action to advance patient-focused and decentralized clinical trialsCancer2023111. doi:10.1002/cncr.35145